# Effects of Beta-Blocker Therapy and Phosphodiesterase Inhibition on Cardiac Neurohormonal Activation

> **NCT00348101** · PHASE3 · COMPLETED · sponsor: **Klinikum Ludwigshafen** · enrollment: 75 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** Combined therapy with enoximone and esmolol

## Key facts

- **NCT ID:** NCT00348101
- **Lead sponsor:** Klinikum Ludwigshafen
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** —
- **Final completion:** 2007-05
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2007-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00348101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00348101, "Effects of Beta-Blocker Therapy and Phosphodiesterase Inhibition on Cardiac Neurohormonal Activation". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT00348101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*